Scarica l'app Stockscreener
40.84
0.01%
-0.005
Dopo l'orario di chiusura:
40.83
-0.015
-0.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché APLS Giù?
Forum
Previsione
Precedente Chiudi:
$40.85
Aprire:
$40.85
Volume 24 ore:
2.50M
Relative Volume:
0.50
Capitalizzazione di mercato:
$5.22B
Reddito:
$1.00B
Utile/perdita netta:
$22.39M
Rapporto P/E:
330.73
EPS:
0.1235
Flusso di cassa netto:
$45.01M
1 W Prestazione:
+0.38%
1M Prestazione:
+115.65%
6M Prestazione:
+61.95%
1 anno Prestazione:
+115.31%
Intervallo 1D:
$40.83
$40.88
Intervallo di 1 settimana:
$40.64
$40.88
Portata 52W:
$16.10
$40.88
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Nome
Apellis Pharmaceuticals Inc
Settore
Industria
Telefono
617-977-5700
Indirizzo
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
40.84 | 5.22B | 1.00B | 22.39M | 45.01M | 0.1235 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-13 | Iniziato | Roth Capital | Buy |
| 2026-01-28 | Iniziato | Barclays | Equal Weight |
| 2026-01-21 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-11-06 | Iniziato | Wolfe Research | Peer Perform |
| 2025-10-15 | Iniziato | Wells Fargo | Overweight |
| 2025-09-26 | Downgrade | Goldman | Neutral → Sell |
| 2025-05-09 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-05-09 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Downgrade | Goldman | Buy → Neutral |
| 2024-11-21 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-10-25 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-16 | Iniziato | William Blair | Outperform |
| 2024-05-31 | Iniziato | Piper Sandler | Neutral |
| 2024-02-05 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-12-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-02 | Iniziato | Mizuho | Neutral |
| 2023-10-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-15 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | Reiterato | Citigroup | Buy |
| 2023-08-03 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-08-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-19 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-17 | Ripresa | Stifel | Buy |
| 2022-04-14 | Downgrade | ROTH Capital | Neutral → Sell |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-11-29 | Downgrade | ROTH Capital | Buy → Neutral |
| 2021-09-10 | Reiterato | BMO Capital Markets | Outperform |
| 2021-09-10 | Reiterato | Credit Suisse | Neutral |
| 2021-09-10 | Reiterato | Needham | Buy |
| 2021-09-10 | Reiterato | Oppenheimer | Outperform |
| 2021-09-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-08-19 | Iniziato | Jefferies | Buy |
| 2021-08-19 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-16 | Iniziato | Goldman | Buy |
| 2020-11-19 | Iniziato | Needham | Buy |
| 2020-09-01 | Iniziato | Stifel | Buy |
| 2020-07-20 | Iniziato | ROTH Capital | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Neutral |
| 2020-04-01 | Iniziato | Raymond James | Strong Buy |
| 2020-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-11 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2020-01-07 | Iniziato | SVB Leerink | Mkt Perform |
| 2019-12-19 | Iniziato | BofA/Merrill | Buy |
| 2019-11-22 | Iniziato | Wedbush | Underperform |
| 2019-11-05 | Iniziato | Credit Suisse | Neutral |
| 2019-08-01 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-07-30 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-04-12 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Apellis Pharmaceuticals Inc Borsa (APLS) Ultime notizie
Mizuho reiterates Apellis stock rating citing M&A process details - Investing.com
Mizuho reiterates Apellis stock rating citing M&A process details By Investing.com - Investing.com Canada
Biogen raised to overweight at Piper Sandler on Apellis buyout - MSN
Biogen to acquire Apellis for $5.6B to strengthen immunology portfolio - MSN
Apellis Pharmaceuticals (APLS) hits 2-year high on 140% upside from Biogen merger - MSN
Apellis Pharmaceuticals stock hits 52-week high at 40.87 USD - Investing.com
Apellis Pharmaceuticals stock hits 52-week high at 40.87 USD By Investing.com - Investing.com UK
M&A Class Action Firm Investigating Multiple Mergers - National Today
Biogen stock upgraded at Piper Sandler (BIIB:NASDAQ) - Seeking Alpha
Apellis (APLS) board recommends $41 cash takeover by Biogen with up to $4 CVR - Stock Titan
Biogen (NASDAQ: APLS) bids $41 per share plus up to $4 CVR for Apellis - Stock Titan
Wellington Management Group LLP Significantly Reduces Stake in Apellis Pharmaceuticals Inc - GuruFocus
Support Test: Can Apellis Pharmaceuticals Inc stock outperform in a bear marketMarket Weekly Review & Precise Buy Zone Tips - baoquankhu1.vn
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals and other big stocks moving higher on Tuesday - MSN
Valuation Update: Does Apellis Pharmaceuticals Inc stock have upside surprise potential - baoquankhu1.vn
Biogen lands two fast-growing drugs in blockbuster Apellis deal - MSN
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders? - Sahm
US Market Recap: Will Apellis Pharmaceuticals Inc benefit from geopolitical trendsQuarterly Portfolio Report & High Return Trade Guides - baoquankhu1.vn
Apellis (APLS) director shifts 5,750 trust shares to spouse account - Stock Titan
Apellis Stock More Than Doubles on Biogen News. Here’s What to Know. - Barron's
Trading the Move, Not the Narrative: (APLS) Edition - Stock Traders Daily
Biogen’s Apellis Deal And High Dose SPINRAZA Shift Growth Outlook - Sahm
Are APLS, KORE, CNTA Obtaining Fair Deals for their Shareholders? - Sahm
Apellis Pharmaceuticals Stock Rockets 140% With 6-Day Winning Streak - Trefis
6-Day Rally Sends Apellis Pharmaceuticals Stock Up 140% - Trefis
Apellis Pharmaceuticals stock reaches 52-week high at $40.71 By Investing.com - Investing.com Australia
Biogen (NASDAQ: APLS) readies tender offer for Apellis under March 31, 2026 deal - Stock Titan
Apellis Pharmaceuticals stock reaches 52-week high at $40.71 - Investing.com
Retail Surge: Can Apellis Pharmaceuticals Inc grow without dilution2026 Retail & Community Consensus Stock Picks - baoquankhu1.vn
RBC Adjusts Price Target on Apellis Pharmaceuticals to $41 From $21, Maintains Sector Perform Rating - marketscreener.com
Biogen Taps Alloy Platform To Push Antisense Drug Pipeline Forward - Benzinga
Apellis Pharmaceuticals Acquisition Under Investigation - National Today
Wellington files 13G/A owning 249,635 shares of Apellis (APLS) - Stock Titan
Shareholder Alert: Ademi LLP investigates whether Apellis Pharmaceuticals Inc. is obtaining a ... - Bluefield Daily Telegraph
Shareholder Alert: Ademi LLP investigates whether Apellis - GlobeNewswire
5-Day Rally Sends Apellis Pharmaceuticals Stock Up 139% - Trefis
Apellis Pharmaceuticals Stock Surges 139%, With A 5-Day Winning Spree - Trefis
Biogen (NASDAQ: APLS) files Form 3 on Apellis voting group status - Stock Titan
Biogen Discloses Tender Offer at Apellis with 14.2% Stake - TradingView — Track All Markets
[SCHEDULE 13D] Apellis Pharmaceuticals, Inc. Major Shareholder Acquisition (>5%) - Stock Titan
Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Move into Immunology - FinancialContent
Apellis Pharmaceuticals (NASDAQ:APLS) Reaches New 12-Month HighWhat's Next? - MarketBeat
Biogen Paid a 140% Premium for Apellis. Was the $5.6B Deal Worth It? - TIKR.com
Apellis Stock Soars After Biogen Deal, Momentum Score Surges—Here's What Shareholders Get - Benzinga
Apellis Pharmaceuticals, Inc. (APLS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Apellis surges on $5.6B buyout deal with Biogen - MSN
Biogen’s Apellis Deal Reshapes Growth Outlook And Valuation Story - Yahoo Finance
TD Cowen Maintains Apellis Pharmaceuticals (APLS) Buy Recommendation - MSN
APLS PE Ratio & Valuation, Is APLS Overvalued - Intellectia AI
Biogen Bets Big on Kidney Drugs with USD 5.6 Billion Apellis Pharmaceuticals Deal - Medical Dialogues
Biogen (NASDAQ: BIIB) plans tender offer to acquire Apellis (APLS); materials pending - Stock Titan
Apellis Pharmaceuticals Inc Azioni (APLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):